Please login to the form below

Not currently logged in
Email:
Password:

Biomarker

This page shows the latest Biomarker news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

In the Keytruda plus Lynparza arm, 12% of patients had a 50% or greater reduction in PSA, a biomarker which is elevated in prostate cancer.

Latest news

More from news
Approximately 4 fully matching, plus 241 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest from PMHub

  • Cancer Tissue Diagnostics Market to Be Worth Almost US$ 9648.9 Mn By 2026

    This growth is primarily attributed to factors such as the constantly extending list of cancer biomarkers and the presence of advance healthcare infrastructures in the region.

  • Navigating the antibiotic resistance crisis

    Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians navigating this complex landscape.

  • Three key development areas in the management of multiple sclerosis

    Mark and Fabrice identified three key themes across the meeting:. The use of neurofilament light chain (NfL) levels as a biomarker for disease activity and response to treatment– when neurons or ... Research presented at ECTRIMS shows promise for NfL

  • A4P Bio Consulting Ltd

    As experts in biomarkers, bioanalysis, pharmacokinetics, logistics and quality systems management A4P deliver scientifically robust, regulatory compliant, cost effective and value added solutions for the global life sciences sector.

  • Is the pharma business model ready for precision medicine?

    It exists at the convergence of genomic sequencing, biomarker research, bioinformatics and big data analysis. ... This differs from traditional tumour type or ‘adaptive’ trials where the predictive biomarker is not clearly identified at trial

More from PMHub
Approximately 5 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics